+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
ID07846462

Comparing Low-Dose and Standard-Dose Aspirin Combined With a P2Y12 Inhibitor After PCI to Prevent Cardiac Events

Led by Jilin University · Updated on 2026-10-01

2640

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of two different doses of aspirin 50 mg versus 100 mg once daily combined with a P2Y12 inhibitor in patients who have undergone successful percutaneous coronary intervention PCI and plan to receive at least 12 months of dual antiplatelet therapy. This randomized, open-label trial conducted in China aims to determine whether the lower aspirin dose is not worse than the standard dose in preventing major cardiac and cerebrovascular events, with a focus on Chinese patients. Participants are randomly assigned to receive either 50 mg or 100 mg of enteric-coated aspirin daily combined with a P2Y12 inhibitor, either ticagrelor or clopidogrel, based on clinical guidelines. All participants will continue this dual therapy for at least 12 months following PCI. The trial also includes a follow-up period with visits at 1, 6, and 12 months to assess outcomes and medication adherence. During the study, participants undergo clinical assessments and event verifications at the scheduled visits. Researchers will monitor the occurrence of major adverse cardiac and cerebrovascular events over 12 months, as well as clinically relevant bleeding events and net adverse clinical events. Safety data will be reviewed periodically by a monitoring committee. The total participation duration is 12 months post-randomization.

CONDITIONS

Brief Title

Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI

Research Team

Q

Qian Tong, MD

M

Mingyou 'Zhang', MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here